Akkermansia muciniphila MucT (pasteurised)

Safety evaluation of two A. muciniphila strains (AM02 and AM06) in mice showed no acute toxicity, no treatment-related deaths, and no significant differences in blood parameters, indicating safety for short-term usage.

Comprehensive review documenting that viable A. muciniphila MucT administration ameliorates disease and modulates immune response toward anti-inflammatory states across multiple conditions including metabolic disorders, infections, and cancer immunotherapy response.

First human safety trial of pasteurised A. muciniphila in 20 subjects with excess body weight and metabolic syndrome demonstrated safety and tolerability over three months. Pasteurised form reduced fat mass development, insulin resistance, and dyslipidemia, with effects mediated through the Amuc_1100* outer membrane protein.

Comprehensive review documenting that viable A. muciniphila MucT administration ameliorates disease and modulates immune response toward anti-inflammatory states across multiple conditions including metabolic disorders, infections, and cancer immunotherapy response.

First human safety trial of pasteurised A. muciniphila in 20 subjects with excess body weight and metabolic syndrome demonstrated safety and tolerability over three months. Pasteurised form reduced fat mass development, insulin resistance, and dyslipidemia, with effects mediated through the Amuc_1100* outer membrane protein.

First human safety trial of pasteurised A. muciniphila in 20 subjects with excess body weight and metabolic syndrome demonstrated safety and tolerability over three months. Pasteurised form reduced fat mass development, insulin resistance, and dyslipidemia, with effects mediated through the Amuc_1100* outer membrane protein.

Comprehensive review documenting that viable A. muciniphila MucT administration ameliorates disease and modulates immune response toward anti-inflammatory states across multiple conditions including metabolic disorders, infections, and cancer immunotherapy response.

First human safety trial of pasteurised A. muciniphila in 20 subjects with excess body weight and metabolic syndrome demonstrated safety and tolerability over three months. Pasteurised form reduced fat mass development, insulin resistance, and dyslipidemia, with effects mediated through the Amuc_1100* outer membrane protein.

Comprehensive review documenting that viable A. muciniphila MucT administration ameliorates disease and modulates immune response toward anti-inflammatory states across multiple conditions including metabolic disorders, infections, and cancer immunotherapy response.